Lupin's US sales spike fuels 16% profit rise in early FY27, broad-based momentum continues

Mumbai-based Lupin Ltd reported a 16% increase in quarterly profit, driven by robust sales across its key markets, especially the US, signalling strong start to the financial year amid broad-based growth.

Lupin Ltd has started the financial year with a sharp rise in profit, helped by stronger sales across its main geographies. In a regulatory filing on Thursday, the Mumbai-based drugmaker said consolidated profit after tax increased 16% to ₹1,416.98 crore in the quarter ended June 30, from ₹1,221.46 crore a year earlier. Revenue from operations climbed to ₹8,276.89 crore from ₹6,268.34 crore.

The strongest contribution came from the US, where sales jumped 42.9% to ₹3,434.8 crore. India revenue rose 13.9% to ₹2,379.6 crore, while sales in other developed markets increased 48.3% to ₹1,149.4 crore. The figures point to broad-based momentum rather than reliance on a single market.

Costs also moved higher, with total expenses rising to ₹6,389.83 crore from ₹4,931.84 crore a year earlier. Even so, managing director Nilesh Gupta said the company was pleased to open FY27 with what he called a strong performance, adding that better execution, operational discipline and continued investment in technology and innovation should support profitable growth over the long term.

The latest results extend a run of gains for Lupin. Business Standard has previously reported that net profit rose 37.47% in the December 2025 quarter and 89.04% in the March 2026 quarter, before the company closed the last financial year with revenue of ₹27,487.54 crore and net profit of ₹5,332.84 crore. A separate report from its quarterly results page showed revenue and operating profit also strengthening in the final quarter of FY26, underlining the company’s recent improvement in earnings momentum.